CoChat
Sign Up
Cited by 146

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Advancing engineering design strategies for targeted cancer nanomedicine

Gomerdinger, Victoria F., Nabar, Namita, Hammond, Paula T.·2025·Nature Reviews Cancer
DOI 10.1038/s41568-025-00847-2
Open this paper in CoChat — free account

Abstract

Engineered nanoparticles have greatly expanded cancer treatment by encapsulating and delivering therapeutic and diagnostic agents, otherwise limited by poor pharmacokinetics and toxicity, to target tumour cells. Leveraging our increased understanding of the tumour microenvironment, nanomedicine has expanded to additionally target key tissues and cells implicated in tumorigenesis, such as immune and stromal cells, to improve potency and further mitigate off-target toxicities. To design nanocarriers that overcome the body's physiological barriers to access tumours, the field has explored broader routes of administration and nanoparticle design principles, beyond the enhanced permeation and retention effect. This Review explores the advantages of non-covalent surface modifications of nanoparticles, along with other surface modifications, to modulate nanoparticle trafficking from the injection site, into tumour and lymphoid tissues, to the target cell, and ultimately its subcellular fate. Using electrostatic or other non-covalent techniques, nanoparticle surfaces can be decorated with native and synthetic macromolecules that confer highly precise cell and tissue trafficking. Rational design can additionally minimize detection and clearance by the immune system and prolong half-life - key to maximizing efficacy of therapeutic cargos. Finally, we outline how cancer nanomedicine continues to evolve by incorporating learnings from novel screening technologies, computational approache…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41568-025-00847-2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 301

  1. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986). This seminal paper illustrates the EPR effect, demonstrating high macromolecule accumulation in tumours.
  2. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 65, 271–284 (2000). · DOI · Paper page
  3. Lahooti, B. et al. Targeting endothelial permeability in the EPR effect. J. Control. Rel. 361, 212–235 (2023). · DOI
  4. Sharifi, M. et al. An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment. Cancers 14, 2868 (2022). · DOI
  5. Bertrand, N., Wu, J., Xu, X. Y., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014). · DOI
  6. Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843–856 (2015). · DOI
  7. Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104, 15549–15554 (2007). · DOI
  8. Harrington, K. J. et al. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br. J. Cancer 83, 232–238 (2000). · DOI
  9. Dai, Q. et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 12, 8423–8435 (2018). This work investigates the physical and cellular barriers to intratumoural transport of passive and ligand-targeted nanoparticles and ultimate delivery to cancer cells after intravenous administration. · DOI
  10. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). · DOI · Paper page
  11. Kingston, B. R. et al. Specific endothelial cells govern nanoparticle entry into solid tumors. ACS Nano 15, 14080–14094 (2021). · DOI
  12. Tavares, A. J. et al. Effect of removing Kupffer cells on nanoparticle tumor delivery. Proc. Natl Acad. Sci. USA 114, E10871–E10880 (2017). · DOI
  13. Bae, Y. H. & Park, K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Rel. 153, 198–205 (2011). · DOI
  14. Feng, X. et al. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases: a review. Int. J. Nanomed. 19, 1509–1538 (2024). · DOI
  15. Khang, M. et al. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Sci. Transl. Med. 15, eadi1617 (2023). · DOI
  16. De Andres, J. et al. Intrathecal drug delivery: advances and applications in the management of chronic pain patient. Front. Pain Res. 3, 900566 (2022). · DOI
  17. Niu, L., Chu, L. Y., Burton, S. A., Hansen, K. J. & Panyam, J. Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response. J. Control. Rel. 294, 268–278 (2019). · DOI
  18. Correa, S. et al. Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry. ACS Nano 14, 2224–2237 (2020). · DOI
  19. Gao, N. et al. Tumor penetrating theranostic nanoparticles for enhancement of targeted and image-guided drug delivery into peritoneal tumors following intraperitoneal delivery. Theranostics 7, 1689–1704 (2017). · DOI
  20. Wright, A. A. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 33, 2841–2847 (2015). · DOI
  21. Palugan, L. et al. Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. Int. J. Pharm. X 3, 100100 (2021).
  22. Yoon, H. Y. et al. Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer. Expert Opin. Drug Deliv. 17, 1555–1572 (2020). · DOI
  23. Yun, W. S. et al. Recent studies and progress in the intratumoral administration of nano-sized drug delivery systems. Nanomaterials 13, 2225 (2023). · DOI · Paper page
  24. Talebian, S. et al. Biopolymers for antitumor implantable drug delivery systems: recent advances and future outlook. Adv. Mater. 30, 1706665 (2018). · DOI
  25. Lan, X. et al. Microneedle-mediated delivery of lipid-coated cisplatin nanoparticles for efficient and safe cancer therapy. ACS Appl. Mater. Interfaces 10, 33060–33069 (2018). · DOI
  26. Moradi Kashkooli, F., Jakhmola, A., Hornsby, T. K., Tavakkoli, J. & Kolios, M. C. Ultrasound-mediated nano drug delivery for treating cancer: fundamental physics to future directions. J. Control. Rel. 355, 552–578 (2023). · DOI
  27. Wang, Y. et al. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat. Biomed. Eng. 5, 1048–1058 (2021). · DOI
  28. D’Amico, R. S., Aghi, M. K., Vogelbaum, M. A. & Bruce, J. N. Convection-enhanced drug delivery for glioblastoma: a review. J. Neurooncol. 151, 415–427 (2021). · DOI
  29. Pickering, A. J. et al. Layer-by-layer polymer functionalization improves nanoparticle penetration and glioblastoma targeting in the brain. ACS Nano 17, 24154–24169 (2023). · DOI
  30. Wicki, A., Witzigmann, D., Balasubramanian, V. & Huwyler, J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Rel. 200, 138–157 (2015). · DOI
  31. Magnussen, A. L. & Mills, I. G. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br. J. Cancer 125, 324–336 (2021). · DOI · Paper page
  32. Mpekris, F. et al. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl Acad. Sci. USA 117, 3728–3737 (2020). · DOI
  33. Hartl, N., Adams, F. & Merkel, O. M. From adsorption to covalent bonding: apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood-brain barrier. Adv. Ther. 4, 2000092 (2021). · DOI
  34. Chen, S. et al. Effect of cationic charge density on transcytosis of polyethylenimine. Biomacromolecules 22, 5139–5150 (2021). · DOI
  35. Lamson, N. G. et al. Trafficking through the blood–brain barrier is directed by core and outer surface components of layer-by-layer nanoparticles. Bioeng. Transl. Med. 9, e10636 (2024). · DOI
  36. Kreuter, J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 71, 2–14 (2014). · DOI · Paper page
  37. Wiley, D. T., Webster, P., Gale, A. & Davis, M. E. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc. Natl Acad. Sci. USA 110, 8662–8667 (2013). · DOI
  38. Georgieva, J. V. et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood–brain barrier endothelial cells in vitro. Mol. Ther. 19, 318–325 (2011). · DOI
  39. Saucier-Sawyer, J. K. et al. Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. J. Control. Rel. 232, 103–112 (2016). · DOI
  40. Biddlestone-Thorpe, L. et al. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv. Drug Deliv. Rev. 64, 605–613 (2012). · DOI
  41. Curtis, C., Toghani, D., Wong, B. & Nance, E. Colloidal stability as a determinant of nanoparticle behavior in the brain. Colloids Surf. B Biointerfaces 170, 673–682 (2018). · DOI
  42. Jiang, X., Zhao, H. & Li, W. Microneedle-mediated transdermal delivery of drug-carrying nanoparticles. Front. Bioeng. Biotechnol. 10, 840395 (2022). · DOI
  43. Koenitz, L., Crean, A. & Vucen, S. Pharmacokinetic differences between subcutaneous injection and intradermal microneedle delivery of protein therapeutics. Eur. J. Pharm. Biopharm. 204, 114517 (2024). · DOI
  44. Wang, J. C. et al. Microneedles-mediated intradermal delivery of paclitaxel/anti-PD-1 for efficient and safe triple-negative breast cancer therapy. Adv. Ther. 7, 2300362 (2024). · DOI
  45. Schudel, A., Francis, D. M. & Thomas, S. N. Material design for lymph node drug delivery. Nat. Rev. Mater. 4, 415–428 (2019). · DOI
  46. Yousefpour, P., Ni, K. & Irvine, D. J. Targeted modulation of immune cells and tissues using engineered biomaterials. Nat. Rev. Bioeng. 1, 107–124 (2023). · DOI
  47. Ceelen, W. P. & Flessner, M. F. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat. Rev. Clin. Oncol. 7, 108–115 (2010). · DOI
  48. Dakwar, G. R. et al. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — mission possible? Adv. Drug Deliv. Rev. 108, 13–24 (2017). · DOI
  49. Aznar, M. A. et al. Intratumoral delivery of immunotherapy — act locally, think globally. J. Immunol. 198, 31–39 (2017). · DOI
  50. Champiat, S. et al. Intratumoral immunotherapy: from trial design to clinical practice. Clin. Cancer Res. 27, 665–679 (2021). · DOI
  51. Huang, A. et al. Human intratumoral therapy: linking drug properties and tumor transport of drugs in clinical trials. J. Control. Rel. 326, 203–221 (2020). · DOI
  52. Hamid, O., Ismail, R. & Puzanov, I. Intratumoral immunotherapy — update 2019. Oncologist 25, e423–e438 (2019). · DOI
  53. Holback, H. & Yeo, Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 28, 1819–1830 (2011). · DOI
  54. J. Saadh, M. et al. Nanoparticle-based targeting of pancreatic tumor stroma and extracellular matrix: a promising approach for improved treatment. J. Drug Deliv. Sci. Technol. 99, 105938 (2024). · DOI
  55. Herrera, V. L. M. et al. Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis. Nanomedicine 11, 1001–1015 (2016). · DOI
  56. Zhang, B. et al. Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles. Biomaterials 35, 4088–4098 (2014). · DOI
  57. Passos, J. S., Lopes, L. B. & Panitch, A. Collagen-binding nanoparticles for paclitaxel encapsulation and breast cancer treatment. ACS Biomater. Sci. Eng. 9, 6805–6820 (2023). · DOI
  58. Chaib, M., Chauhan, S. C. & Makowski, L. Friend or foe? recent strategies to target myeloid cells in cancer. Front. Cell Dev. Biol. 8, 351 (2020). · DOI
  59. Vu-Quang, H. et al. Carboxylic mannan-coated iron oxide nanoparticles targeted to immune cells for lymph node-specific MRI in vivo. Carbohydr. Polym. 88, 780–788 (2012). · DOI
  60. Hudgins, P. A., Anzai, Y., Morris, M. R. & Lucas, M. A. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. Am. J. Neuroradiol. 23, 649–656 (2002).
  61. Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018). · DOI · Paper page
  62. Xu, L. et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J. Hematol. Oncol. 15, 87 (2022). This review illustrates the complex role of the tumour immune environment and therapeutic strategies to modulate said environment to promote anticancer responses. · DOI
  63. Zhang, C. et al. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. J. Control. Rel. 256, 170–181 (2017). · DOI
  64. Xu, Y. et al. Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity. Biomaterials 284, 121489 (2022). · DOI
  65. Cao, Y. et al. Dendritic cell-mimicking nanoparticles promote mrna delivery to lymphoid organs. Adv. Sci. 10, 2302423 (2023). · DOI
  66. Mortara, L. et al. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front. Immunol. 9, 2905 (2018). · DOI
  67. Chu, J. et al. Natural killer cells: a promising immunotherapy for cancer. J. Transl. Med. 20, 240 (2022). · DOI
  68. Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P. & Nelson, B. H. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat. Rev. Cancer 22, 414–430 (2022). · DOI
  69. Saw, P. E., Chen, J. & Song, E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer 8, 527–555 (2022). This review describes the role of CAFs in tumour progression and therapeutic strategies that are utilized to target this cell population. · DOI
  70. Xiao, Z. & Puré, E. The fibroinflammatory response in cancer. Nat. Rev. Cancer 25, 399–425 (2025). · DOI
  71. Zheng, A., Wei, Y., Zhao, Y., Zhang, T. & Ma, X. The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer. Front. Immunol. 13, 1013506 (2022). · DOI
  72. Zhao, Y. et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc. Natl Acad. Sci. USA 116, 2210–2219 (2019). · DOI
  73. Zhang, Y., Wu, J. L., Lazarovits, J. & Chan, W. C. An analysis of the binding function and structural organization of the protein corona. J. Am. Chem. Soc. 142, 8827–8836 (2020). · DOI
  74. Grunér, M. S., Kauscher, U., Linder, M. & Monopoli, M. An environmental route of exposure affects the formation of nanoparticle coronas in blood plasma. J. Proteom. 137, 52–58 (2016). · DOI
  75. Mosquera, J., García, I., Henriksen-Lacey, M., González-Rubio, G. & Liz-Marzán, L. M. Reducing protein corona formation and enhancing colloidal stability of gold nanoparticles by capping with silica monolayers. Chem. Mater. 31, 57–61 (2018). · DOI
  76. Hadjidemetriou, M., Al-Ahmady, Z. & Kostarelos, K. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8, 6948–6957 (2016). · DOI
  77. Xiao, W. & Gao, H. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system. Int. J. Pharm. 552, 328–339 (2018). · DOI
  78. Lazarovits, J. et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS Nano 13, 8023–8034 (2019). · DOI
  79. Ngo, W. et al. Identifying cell receptors for the nanoparticle protein corona using genome screens. Nat. Chem. Biol. 18, 1023–1031 (2022). · DOI
  80. Montizaan, D. et al. Genome-wide forward genetic screening to identify receptors and proteins mediating nanoparticle uptake and intracellular processing. Nat. Nanotechnol. 19, 1022–1031 (2024). This work identified cell receptors, including lipoprotein receptors and glycosaminoglycans, implicated in nanoparticle uptake, through a genome-wide screening. · DOI
  81. Mirshafiee, V., Mahmoudi, M., Lou, K., Cheng, J. & Kraft, M. L. Protein corona significantly reduces active targeting yield. Chem. Commun. 49, 2557–2559 (2013). · DOI
  82. Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137–143 (2013). · DOI · Paper page
  83. Wang, H. et al. Interrogation of folic acid-functionalized nanomedicines: the regulatory roles of plasma proteins reexamined. ACS Nano 14, 14779–14789 (2020). · DOI
  84. Xiao, W. et al. Influence of ligands property and particle size of gold nanoparticles on the protein adsorption and corresponding targeting ability. Int. J. Pharm. 538, 105–111 (2018). · DOI
  85. Bilardo, R., Traldi, F., Vdovchenko, A. & Resmini, M. Influence of surface chemistry and morphology of nanoparticles on protein corona formation. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 14, e1788 (2022). · DOI
  86. Barz, M., Parak, W. J. & Zentel, R. Concepts and approaches to reduce or avoid protein corona formation on nanoparticles: challenges and opportunities. Adv. Sci. 11, 2402935 (2024). · DOI
  87. Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021). · DOI · Paper page
  88. Chen, D., Parayath, N., Ganesh, S., Wang, W. & Amiji, M. The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models. Nanoscale 11, 18806–18824 (2019). · DOI
  89. Caracciolo, G. et al. Human biomolecular corona of liposomal doxorubicin: the overlooked factor in anticancer drug delivery. ACS Appl. Mater. Interfaces 10, 22951–22962 (2018). · DOI
  90. Papi, M. et al. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells. Nanoscale 9, 10327–10334 (2017). · DOI
  91. Gao, Y., Joshi, M., Zhao, Z. & Mitragotri, S. PEGylated therapeutics in the clinic. Bioeng. Transl. Med. 9, e10600 (2024). This review presents the range of investigational and clinically approved PEGylated therapeutics, PEG engineering strategies and challenges. · DOI
  92. Chen, D., Ganesh, S., Wang, W. & Amiji, M. The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. Nanoscale 11, 8760–8775 (2019). · DOI
  93. Pozzi, D. et al. Effect of polyethyleneglycol (PEG) chain length on the bio–nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6, 2782–2792 (2014). · DOI · Paper page
  94. Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022). · DOI
  95. Besin, G. et al. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties. Immunohorizons 3, 282–293 (2019). This study demonstrates the accelerated blood clearance of repeat doses of intravenous PEGylated lipid nanoparticles and illustrates a B cell-driven response. · DOI
  96. Wang, X., Ishida, T. & Kiwada, H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Rel. 119, 236–244 (2007). · DOI · Paper page
  97. Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. npj Vaccines 8, 169 (2023). · DOI
  98. Schöttler, S. et al. Protein adsorption is required for stealth effect of poly (ethylene glycol)-and poly (phosphoester)-coated nanocarriers. Nat. Nanotechnol. 11, 372–377 (2016). · DOI · Paper page
  99. Overby, C., Park, S., Summers, A. & Benoit, D. S. W. Zwitterionic peptides: tunable next-generation stealth nanoparticle modifications. Bioact. Mater. 27, 113–124 (2023).
  100. García, K. P. et al. Zwitterionic-coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small 10, 2516–2529 (2014). · DOI
  101. Müller, J. et al. Coating nanoparticles with tunable surfactants facilitates control over the protein corona. Biomaterials 115, 1–8 (2017). · DOI
  102. Simon, J. et al. Noncovalent targeting of nanocarriers to immune cells with polyphosphoester-based surfactants in human blood plasma. Adv. Sci. 6, 1901199 (2019). This study demonstrates the multifunctional design of polymers serving as a nanoparticle surface chemistry to increase targeting to specific cells and also reduce nonspecific uptake by off-target cells. · DOI
  103. Sarparanta, M. et al. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Mol. Pharm. 9, 654–663 (2012). · DOI
  104. Moghimi, S. M., Muir, I., Illum, L., Davis, S. S. & Kolb-Bachofen, V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta Mol. Cell Res. 1179, 157–165 (1993). · DOI
  105. Shi, D. et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv. Drug Deliv. Rev. 180, 114079 (2022). · DOI · Paper page
  106. Hui, Y. et al. Role of nanoparticle mechanical properties in cancer drug delivery. ACS Nano 13, 7410–7424 (2019). This review presents how mechanical properties of nanoparticles affect uptake and distribution, highlighting other physiochemical properties of nanoparticles that have a role in their trafficking. · DOI
  107. Kong, S. M., Costa, D. F., Jagielska, A., Vliet, K. J. V. & Hammond, P. T. Stiffness of targeted layer-by-layer nanoparticles impacts elimination half-life, tumor accumulation, and tumor penetration. Proc. Natl Acad. Sci. USA 118, e2104826118 (2021). · DOI
  108. Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. W. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 8, 5696–5706 (2014). · DOI
  109. Cong, V. T. et al. Can the shape of nanoparticles enable the targeting to cancer cells over healthy cells? Adv. Funct. Mater. 31, 2007880 (2021). · DOI
  110. Elci, S. G. et al. Surface charge controls the suborgan biodistributions of gold nanoparticles. ACS Nano 10, 5536–5542 (2016). · DOI
  111. Zelepukin, I. V. et al. Fast processes of nanoparticle blood clearance: comprehensive study. J. Control. Rel. 326, 181–191 (2020). · DOI
  112. Anselmo, A. C. et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano 9, 3169–3177 (2015). · DOI
  113. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505–515 (2008). · DOI · Paper page
  114. Guo, P. et al. Nanoparticle elasticity directs tumor uptake. Nat. Commun. 9, 130 (2018). · DOI
  115. Marques, A. C., Costa, P. J., Velho, S. & Amaral, M. H. Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J. Control. Rel. 320, 180–200 (2020). · DOI
  116. Chen, F. et al. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat. Commun. 9, 4141 (2018). · DOI
  117. Schau, I. et al. Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis. Sci. Rep. 9, 3299 (2019). · DOI
  118. Zhang, C. et al. Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody–DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer. Sci. Rep. 10, 22015 (2020). · DOI
  119. Dissanayake, S., Denny, W. A., Gamage, S. & Sarojini, V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J. Control. Rel. 250, 62–76 (2017). · DOI
  120. Wu, X., Chen, J., Wu, M. & Zhao, J. X. Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics 5, 322–344 (2015). · DOI
  121. Farran, B. et al. Folate-conjugated nanovehicles: strategies for cancer therapy. Mater. Sci. Eng. C 107, 110341 (2020). · DOI
  122. Koneru, T. et al. Transferrin: biology and use in receptor-targeted nanotherapy of gliomas. ACS Omega 6, 8727–8733 (2021). · DOI
  123. Kizhakkanoodan, K. S., Rallapalli, Y., Praveena, J., Acharya, S. & Guru, B. R. Cancer nanomedicine: emergence, expansion, and expectations. SN Appl. Sci. 5, 385 (2023). · DOI
  124. Ly, P.-D. et al. Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol. 6, 1456939 (2024). · DOI
  125. Richardson, J. J. et al. Innovation in layer-by-layer assembly. Chem. Rev. 116, 14828–14867 (2016). · DOI
  126. Such, G. K., Johnston, A. P. R. & Caruso, F. Engineered hydrogen-bonded polymer multilayers: from assembly to biomedical applications. Chem. Soc. Rev. 40, 19–29 (2011). · DOI
  127. Monge, C., Almodovar, J., Boudou, T. & Picart, C. Spatio-temporal control of LbL films for biomedical applications: from 2D to 3D. Adv. Healthc. Mater. 4, 811–830 (2015). · DOI
  128. Morton, S. W., Poon, Z. & Hammond, P. T. The architecture and biological performance of drug-loaded LbL nanoparticles. Biomaterials 34, 5328–5335 (2013). · DOI
  129. Boyer, C. et al. Glycopolymer decoration of gold nanoparticles using a LbL approach. Macromolecules 43, 3775–3784 (2010). · DOI
  130. Peng, Q. et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials 34, 8521–8530 (2013). · DOI · Paper page
  131. Dal Magro, R. et al. Artificial apolipoprotein corona enables nanoparticle brain targeting. Nanomed. Nanotechnol. Biol. Med. 14, 429–438 (2018). · DOI
  132. Kim, J. et al. Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma. Proc. Natl Acad. Sci. USA 117, 24205–24212 (2020). · DOI
  133. Caracciolo, G. et al. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1,2-dioleoyl-3-trimethylammonium propane/DNA nanoparticles. ACS Appl. Mater. Interfaces 5, 13171–13179 (2013). · DOI
  134. Tonigold, M. et al. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona. Nat. Nanotechnol. 13, 862–869 (2018). This work demonstrates that nanoparticles with non-covalently adsorbed antibodies outperform those with covalently attached antibodies at targeting, even upon protein corona formation. · DOI
  135. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 7, 5577–5591 (2012). · DOI
  136. Sekar, R. P. et al. Poly(l-glutamic acid) augments the transfection performance of lipophilic polycations by overcoming tradeoffs among cytotoxicity, pDNA delivery efficiency, and serum stability. RSC Appl. Polym. 2, 701–718 (2024). · DOI
  137. Wang, C. et al. Poly(α-glutamic acid) combined with polycation as serum-resistant carriers for gene delivery. Int. J. Pharm. 398, 237–245 (2010). · DOI
  138. Boehnke, N., Dolph, K. J., Juarez, V. M., Lanoha, J. M. & Hammond, P. T. Electrostatic conjugation of nanoparticle surfaces with functional peptide motifs. Bioconjug. Chem. 31, 2211–2219 (2020). · DOI
  139. Gessner, I., Klimpel, A., Klußmann, M., Neundorf, I. & Mathur, S. Interdependence of charge and secondary structure on cellular uptake of cell penetrating peptide functionalized silica nanoparticles. Nanoscale Adv. 2, 453–462 (2020). · DOI
  140. Conte, C. et al. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer. Int. J. Pharm. 633, 122618 (2023). · DOI
  141. Lesley, J., Hascall, V. C., Tammi, M. & Hyman, R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 275, 26967–26975 (2000). · DOI
  142. Dubacheva, G. V., Curk, T., Auzély-Velty, R., Frenkel, D. & Richter, R. P. Designing multivalent probes for tunable superselective targeting. Proc. Natl Acad. Sci. USA 112, 5579–5584 (2015). · DOI
  143. Passos Gibson, V. et al. Hyaluronan decorated layer-by-layer assembled lipid nanoparticles for miR-181a delivery in glioblastoma treatment. Biomaterials 302, 122341 (2023). · DOI
  144. Sacks, J. D. & Barbolina, M. V. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules 5, 3051–3066 (2015). · DOI
  145. Mattheolabakis, G., Milane, L., Singh, A. & Amiji, M. M. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J. Drug Target. 23, 605–618 (2015). · DOI · Paper page
  146. Almalik, A. et al. Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of the formed protein corona. Sci. Rep. 7, 10542 (2017). · DOI
  147. Martens, T. F. et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J. Control. Rel. 202, 83–92 (2015). · DOI
  148. Tian, H. et al. Uniform core–shell nanoparticles with thiolated hyaluronic acid coating to enhance oral delivery of insulin. Adv. Healthc. Mater. 7, 1800285 (2018). · DOI
  149. Zhou, M. et al. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Deliv. 25, 716–722 (2018). · DOI
  150. Nabar, N., Dacoba, T. G., Covarrubias, G., Romero-Cruz, D. & Hammond, P. T. Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies. Proc. Natl Acad. Sci. USA 121, e2307809121 (2024). · DOI
  151. Deiss-Yehiely, E. et al. Surface presentation of hyaluronic acid modulates nanoparticle-cell association. Bioconjug. Chem. 33, 2065–2075 (2022). This work investigates the impact of nanoparticle surface modification with covalent versus adsorbed polymer as well as polymer architecture on cell association. · DOI
  152. Vasić, K. et al. Structural and magnetic characteristics of carboxymethyl dextran coated magnetic nanoparticles: from characterization to immobilization application. React. Funct. Polym. 148, 104481 (2020). · DOI
  153. Huang, B. et al. Amphoteric natural starch-coated polymer nanoparticles with excellent protein corona-free and targeting properties. Nanoscale 12, 5834–5847 (2020). · DOI
  154. Min, K. A., Yu, F., Yang, V. C., Zhang, X. & Rosania, G. R. Transcellular transport of heparin-coated magnetic iron oxide nanoparticles (Hep-MION) under the influence of an applied magnetic field. Pharmaceutics 2, 119–135 (2010). · DOI
  155. Geijtenbeek, T. B. H. & Gringhuis, S. I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9, 465–479 (2009). · DOI
  156. Vu-Quang, H. et al. Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging. Carbohydr. Polym. 87, 1159–1168 (2012). · DOI
  157. Kalia, N., Singh, J. & Kaur, M. The role of dectin-1 in health and disease. Immunobiology 226, 152071 (2021). · DOI
  158. Raynal, I. et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Investig. Radiol. 39, 56–63 (2004). · DOI
  159. Cambi, A. & Figdor, C. G. Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell Biol. 15, 539–546 (2003). · DOI
  160. Lee, R. T. et al. Survey of immune-related, mannose/fucose-binding C-type lectin receptors reveals widely divergent sugar-binding specificities. Glycobiology 21, 512–520 (2011). · DOI
  161. Chen, F., Huang, G. & Huang, H. Sugar ligand-mediated drug delivery. Future Med. Chem. 12, 161–171 (2020). · DOI
  162. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009). · DOI · Paper page
  163. Saini, K. & Bandyopadhyaya, R. Transferrin-conjugated polymer-coated mesoporous silica nanoparticles loaded with gemcitabine for killing pancreatic cancer cells. ACS Appl. Nano Mater. 3, 229–240 (2020). · DOI
  164. Stevens, D. M. et al. Application of a scavenger receptor A1-targeted polymeric prodrug platform for lymphatic drug delivery in HIV. Mol. Pharm. 17, 3794–3812 (2020). · DOI
  165. Sun, C. et al. Polymeric nanomedicine with “Lego” surface allowing modular functionalization and drug encapsulation. ACS Appl. Mater. Interfaces 10, 25090–25098 (2018). · DOI
  166. Kim, S. et al. Cucurbit[6]uril-based polymer nanocapsules as a non-covalent and modular bioimaging platform for multimodal in vivo imaging. Mater. Horiz. 4, 450–455 (2017). · DOI
  167. Hu, C.-M. J. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015). · DOI
  168. Ren, X. et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials 92, 13–24 (2016). · DOI
  169. Rao, L. et al. Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl. Mater. Interfaces 9, 2159–2168 (2017). This study demonstrated that erythrocyte membrane coatings on nanoparticles notably reduce protein adsorption and preserve the targeting abilities of other surface ligands. · DOI
  170. Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011). · DOI
  171. Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8, 61–68 (2013). · DOI
  172. Pitchaimani, A. et al. Biomimetic natural killer membrane camouflaged polymeric nanoparticle for targeted bioimaging. Adv. Funct. Mater. 29, 1806817 (2019). · DOI
  173. Cao, H. et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10, 7738–7748 (2016). · DOI
  174. Kang, T. et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 11, 1397–1411 (2017). · DOI
  175. Chen, Z. et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10, 10049–10057 (2016). · DOI
  176. Liu, Z. et al. Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo. Proc. Natl Acad. Sci. USA 118, e2022769118 (2021). · DOI
  177. Ma, X. et al. Tumor–antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano 17, 2341–2355 (2023). · DOI
  178. Fang, R. H. et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14, 2181–2188 (2014). · DOI
  179. Kou, L. et al. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front. Pharmacol. 9, 27 (2018). · DOI
  180. de Almeida, M. S. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397–5434 (2021). · DOI
  181. Rennick, J. J., Johnston, A. P. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021). This review presents advances in understanding cellular uptake of nanoparticles and discusses limitations and alternatives to experimental approaches to study endocytosis. · DOI
  182. Chakraborty, A. & Jana, N. R. Clathrin to lipid raft-endocytosis via controlled surface chemistry and efficient perinuclear targeting of nanoparticle. J. Phys. Chem. Lett. 6, 3688–3697 (2015). · DOI
  183. Rewatkar, P. V., Parton, R. G., Parekh, H. S. & Parat, M.-O. Are caveolae a cellular entry route for non-viral therapeutic delivery systems? Adv. Drug Deliv. Rev. 91, 92–108 (2015). · DOI
  184. Hong, E. et al. Structure and composition define immunorecognition of nucleic acid nanoparticles. Nano Lett. 18, 4309–4321 (2018). · DOI
  185. França, A. et al. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine 6, 1175–1188 (2011). · DOI
  186. Cai, H., Liang, Z., Huang, W., Wen, L. & Chen, G. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery. Int. J. Pharm. 532, 55–65 (2017). · DOI
  187. Tan, X. et al. Cell-penetrating peptide together with PEG-modified mesostructured silica nanoparticles promotes mucous permeation and oral delivery of therapeutic proteins and peptides. Biomater. Sci. 7, 2934–2950 (2019). · DOI
  188. Margus, H., Arukuusk, P., Langel, U. & Pooga, M. Characteristics of cell-penetrating peptide/nucleic acid nanoparticles. Mol. Pharm. 13, 172–179 (2016). · DOI
  189. He, Z. et al. Scalable production of core–shell nanoparticles by flash nanocomplexation to enhance mucosal transport for oral delivery of insulin. Nanoscale 10, 3307–3319 (2018). · DOI
  190. Dalal, C. & Jana, N. R. Galactose multivalency effect on the cell uptake mechanism of bioconjugated nanoparticles. J. Phys. Chem. C 122, 25651–25660 (2018). · DOI
  191. Dalal, C., Saha, A. & Jana, N. R. Nanoparticle multivalency directed shifting of cellular uptake mechanism. J. Phys. Chem. C 120, 6778–6786 (2016). · DOI
  192. Moradi, E., Vllasaliu, D., Garnett, M., Falcone, F. & Stolnik, S. Ligand density and clustering effects on endocytosis of folate modified nanoparticles. RSC Adv. 2, 3025–3033 (2012). · DOI
  193. Abstiens, K., Gregoritza, M. & Goepferich, A. M. Ligand density and linker length are critical factors for multivalent nanoparticle–receptor interactions. ACS Appl. Mater. Interfaces 11, 1311–1320 (2018). · DOI
  194. Cao, J. et al. The effects of ligand valency and density on the targeting ability of multivalent nanoparticles based on negatively charged chitosan nanoparticles. Colloids Surf. B Biointerfaces 161, 508–518 (2018). · DOI
  195. Ye, Z. et al. Tumour‐targeted drug delivery with mannose‐functionalized nanoparticles self‐assembled from amphiphilic β‐cyclodextrins. Chemistry 22, 15216–15221 (2016). · DOI
  196. Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017). · DOI · Paper page
  197. Kube, S. et al. Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins. Langmuir 33, 1051–1059 (2017). · DOI
  198. Ermilova, I. & Swenson, J. DOPC versus DOPE as a helper lipid for gene-therapies: molecular dynamics simulations with DLin-MC3-DMA. Phys. Chem. Chem. Phys. 22, 28256–28268 (2020). · DOI
  199. Parodi, A. et al. Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers. Nanomedicine 10, 1923–1940 (2015). · DOI
  200. Kodama, Y. et al. Quaternary complexes modified from pDNA and poly-l-lysine complexes to enhance pH-buffering effect and suppress cytotoxicity. J. Pharm. Sci. 104, 1470–1477 (2015). · DOI

200 of 301 shown

Cited by

Sorted by citations

See all 146

Metadata

Authors
Gomerdinger, V. F., Nabar, N., & Hammond, P. T.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2025-08-01
Volume
25
Issue
9
Pages
657-683
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/s41568-025-00847-2
Cited by
146
References
23
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review